IDT and Agilent Technologies Sign Agreement to Offer Oligo Synthesis Encompassing Full Spectrum of Drug Development

Integrated DNA Technologies Inc. (IDT) and Agilent Technologies have signed an agreement to harmonize the companies’ chemistry, processes and analytical techniques, and to provide reciprocal referrals for synthetic oligonucleotides. This coordinated approach to serving customers will help end users reduce the time and costs typically spent when transitioning from the research stage to clinical development.

The agreement forms a complete developmental pathway for customers, including:

• screening and small-scale products produced at all IDT facilities;
• mid-scale products, such as products for animal studies, produced by the IDT Belgium facility; and
• large-scale quantities produced by Agilent’s Nucleic Acid Solutions Division for use as active pharmaceutical ingredients (API) in clinical-trial and marketed-drug production; Agilent’s oligos comply with the pharmaceutical GMP guidelines and ICH Q7.

“This agreement benefits both companies by broadening our customer base, but it ultimately benefits the life science research community,” said Trey Martin, chief operating officer at IDT. “We will now be able to offer researchers a bench-to-bedside oligonucleotide manufacturing package, featuring harmonized manufacturing methods from basic research scales through API manufacturing,”

“Our alliance will provide a competitive advantage to IDT and Agilent customers by significantly reducing the time and costs traditionally associated with the transition from research into clinical development,” said James Powell, general manager of Agilent’s Nucleic Acid Solutions Division. “In addition, by combining the expertise of Agilent and IDT, we will be able to offer best-in-class synthetic oligonucleotide manufacturing solutions to our customers.”